NCT05341947View on ClinicalTrials.gov

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Recurrent Glioblastoma
Interventions
BIOLOGICAL

Activated T cells

Activated T cells (ATC) administered intravenously at one timepoint

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Kairos Pharma
All Listed Sponsors
collaborator

Kairos Pharma

UNKNOWN

lead

Jeremy Rudnick, M.D

OTHER